Meeting
2021 ASCO Annual Meeting
TNB585.001: A multicenter, phase 1, open-label, dose-escalation and expansion study of tnb-585, a bispecific T-cell engager targeting PSMA in subjects with metastatic castrate resistant prostate cancer.
Presenter
Ben Buelow, MD, PhD
TeneoBio, Inc.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Prostate, Testicular, and Penile
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer– Advanced/Castrate-Resistant
Clinical Trial Registration Number
NCT04740034
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr TPS5092)
DOI
10.1200/JCO.2021.39.15_suppl.TPS5092
Abstract #
TPS5092
Poster Bd #
Online Only
Abstract Disclosures
Similar Videos & Slides
Speaker: Panel Discussion
Videos & Slides
2021 Genitourinary Cancers Symposium
A phase II, multicenter, randomized, open-label study to evaluate the safety and tolerability of proxalutamide (GT0918) in subjects with metastatic castrate-resistant prostate cancer (mCRPC).
Speaker: Tie Zhou
Speaker: Jiping Wang, MD, PhD
Videos & Slides
2024 ASCO Annual Meeting
A clinical-genetic (CG) circulating tumor DNA (ctDNA)-based prognostic model for predicting overall survival (OS) in men with metastatic castrate-resistant prostate cancer (mCRPC) treated with potent androgen receptor inhibition (Alliance).
Speaker: Susan Halabi, PhD, FASCO